Bayer’s USD 62 bn Monsanto bid is making the rounds this morning. The move is giving investors pause, with the German company’s stock down significantly since the agreement was first revealed, according to Bloomberg. “Part of the scepticism … appears to stem from a belief that Bayer will have to sweeten its [USD 122]-a-share offer, which was already at a 37 per cent premium to Monsanto’s undisturbed stock price,” according to the Financial Times (paywall). “The danger is that you start then having discussions about how you are going to fund a higher offer, because they are already stretching the balance sheet,” Andrea Williams, a fund manager at Royal London Asset Management Co., told Bloomberg.